NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Price Target & More

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 EPS for the quarter, missing analysts' consensus estimates of $5.08 by $0.41. The biopharmaceutical company earned $1.51 billion during the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The business's quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.92 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

24 equities research analysts have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $290.00 to $593.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $421.1667 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Ratings for Regeneron Pharmaceuticals.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Regeneron Pharmaceuticals include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS) and Takeda Pharmaceutical (TKPYY).

Headlines about REGN stock have trended somewhat positive on Thursday, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.19 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.51 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SANOFI (95.60%), Manning & Napier Group LLC (0.48%), Assenagon Asset Management S.A. (0.11%), Bank of Montreal Can (0.04%), Retirement Systems of Alabama (0.03%) and Nippon Life Global Investors Americas Inc. (0.03%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Westpac Banking Corp, Boston Advisors LLC, Nippon Life Global Investors Americas Inc., Calamos Advisors LLC, Gateway Investment Advisers LLC, Retirement Systems of Alabama and Xact Kapitalforvaltning AB. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Manning & Napier Group LLC, Financial & Investment Management Group Ltd., Essex Investment Management Co. LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, Cito Capital Group LLC and Amalgamated Bank. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $365.98.

Regeneron Pharmaceuticals has a market capitalization of $39.28 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]